Susan Moore
Family · Wytheville, VANPI 1770593212
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $370,720 of the $437,874 with a category attached, or 84.7%. AbbVie accounts for 77.1% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2023 at $121,540 and has fallen 66.2% since, to $41,072 in 2025. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,284 payments — averaging $341.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$338K
- Amgen$60K
- Axsome Therapeutics, Inc.$34K
- Novo Nordisk$870
- AstraZeneca$674
- Takeda Pharmaceuticals U.S.A., Inc.$544
- plus $4K from 38 others
What the payments were for
- Consulting fees$16,6644%
- Speaking & faculty fees$370,72085%
- Travel & lodging$34,5668%
- Food & beverage$15,9094%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$437,874 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 31 | $187,039 |
| OzempicSemaglutide | 133 | $167,228 |
| MounjaroTirzepatide | 106 | $131,291 |
| EliquisApixaban | 84 | $91,422 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 96 | $86,994 |
| VraylarCariprazine Hcl | 35 | $68,461 |
| FarxigaDapagliflozin Propanediol | 49 | $45,071 |
| Repatha SureclickEvolocumab | 50 | $43,128 |
| JardianceEmpagliflozin | 33 | $39,069 |
| LinzessLinaclotide | 43 | $35,122 |
| RybelsusSemaglutide | 31 | $30,135 |
| Nurtec OdtRimegepant Sulfate | 15 | $28,169 |
| JanuviaSitagliptin Phosphate | 24 | $27,566 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $24,385 |
| TrulicityDulaglutide | 22 | $23,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $870 | $197,363164 claims |
| AmgenOtezla | $60,218 | $187,03931 claims |
| Lilly USA, LLCMounjaro, Trulicity | $416 | $154,545128 claims |
| PfizerEliquis, Nurtec Odt | $341 | $119,59199 claims |
| AbbVieVraylar, Linzess | $337,543 | $103,58378 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $102 | $86,99496 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $674 | $59,00481 claims |
| Boehringer IngelheimJardiance | $64 | $39,06933 claims |
| MerckJanuvia | $33 | $27,56624 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Motegrity | $544 | $26,84852 claims |
| NovartisEntresto | $152 | $12,35916 claims |
| Esperion Therapeutics, Inc.Nexletol | $65 | $11,86618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Wytheville
- Tara ParksWytheville$13K
- Andrea CottonVirginia Beach$696K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.